Ratings Sanofi India Limited NSE India S.E.

Equities

Market Closed - NSE India S.E. Other stock markets 07:43:49 2024-04-26 am EDT			5-day change	1st Jan Change
8,274 ^INR	+1.48%		+0.18%	+2.56%

Apr. 15	Sanofi India Limited Announces Appointment of Flovie Martins as Head of Corporate Communications and Corporate Social Responsibility	CI
Mar. 28	Sanofi India Limited Announces Resignation of Marc-Antoine Lucchini as Non-Executive Director from the Board of Directors, Member of the Nomination and Remuneration Committee	CI

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
With an expected P/E ratio at 32.36 and 29.71 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
SANOFI INDIA LIMITED	+2.56%	2.29B		-
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.34B		B-
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B		B+
SANDOZ GROUP AG	+10.86%	14.09B		-
CIPLA LIMITED	+13.07%	13.64B		B+
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.43B		B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B		B+
THE MEDICINES COMPANY	-0.05%	6.79B	-	-
STADA ARZNEIMITTEL	-8.87%	5.73B	-	-
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B		B+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality